Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Nanosphere respiratory virus subtyping test panel FDA clearance

Nanosphere, a provider of advanced molecular diagnostics systems, has received US Food and Drug Administration (FDA) 510(k) clearance for the Verigene Respiratory Virus Plus Nucleic Acid Test (RV+) on the Verigene System.

The RV+ test expands Nanosphere’s existing test capabilities for the detection of respiratory viruses, lik e the RV+ provides Influenza A, Influenza B, RSV A, and RSV B detection, and further subtypes Influenza A as H1, H3, or 2009 H1N1.

The RV+ test does not contain the recommendation to confirm all negative results with culture-based detection methods.

Nanosphere president and CEO William Moffitt said this timely clearance of RV+ will let Nanosphere offer customers the broadest respiratory virus panel available in the market on a sample-to-result platform.

"Moreover, the RV+ test’s clearance enables molecular respiratory testing to begin moving into mainstream medicine," Moffitt said.

The RV+ automates the steps of viral RNA extraction, multiplexed RT-PCR amplification, and target detection on the Verigene System and requires only a single pipetting step.